证券代码：000078 证券简称：海王生物 公告编号：2024-047 公司分别于 2024 年 4 月 27 日召开的第九届董事局第十五次会议、2024 年 6 月 13 日召开的 2023 年年度股东大会，审议通过了向控股子公司提供财务资助 （包括但不限于借款、委托贷款等）相关的事项。 具体内容详见公司在《中国证券报》《证券时报》《证券日报》《上海证券报》 及巨潮资讯网上披露的相关公告。 深圳市海王生物工程股份有限公司 关于提供财务资助的进展公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 释义： 公司、本公司、海王生物：深圳市海王生物工程股份有限公司 山东兰德：山东兰德医疗器械配送有限公司 甘肃海王：甘肃海王医药有限公司 新疆海王：新疆海王医药有限公司 一、财务资助事项概述 （一）转让控股子公司股权被动形成财务资助 深圳市海王生物工程股份有限公司（以下简称"公司"）分别于 2023 年 7 月 14 日召开的第九届董事局第六次会议及 2023 年 7 月 31 日召开的 2023 年第二次 临时股东大会、2023 年 12 月 8 日召开的第九届董事 ...

证券代码：000078 证券简称：海王生物 公告编号：2024-045 深圳市海王生物工程股份有限公司 关于股东部分股份解押及质押的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 深圳市海王生物工程股份有限公司（以下简称"公司"）控股股东深圳海王集 团股份有限公司（以下简称"海王集团"）合计质押公司股份数量为1,214,318,878 股，占其合计持有公司股份数量的比例为99.83%，占公司总股本的44.14%。公司 控股股东质押的股票均为场外质押，质押在银行等金融机构；质押用途基本为融 资增信用途，不存在质押平仓风险。 公司于近日收到公司控股股东海王集团通知获悉：海王集团因业务需要，办 理了其所持公司部分股份的解押及再质押手续。具体情况如下： 注：本公告中若出现总数与各分项数值之和尾数不符的情况，均为四舍五入原因造 成。 股东名称 是否为控股 股东或第一 大股东及其 一致行动人 本次解除质押股 份数量（股） 占其所持 股份比例 占公司 总股本比例 起始日期 解除日期 质权人 海王集团 是 63,625,000 5.23% 2.31% 202 ...

2023 年年度股东大会的 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话：0755-88286488 传真：0755-88286499 邮编：518026 北京德恒（深圳）律师事务所 关于深圳市海王生物工程股份有限公司 2023 年年度股东大会的法律意见 北京德恒（深圳）律师事务所 关于深圳市海王生物工程股份有限公司 北京德恒（深圳）律师事务所 关于深圳市海王生物工程股份有限公司 2023 年年度股东大会的 法律意见 致：深圳市海王生物工程股份有限公司 深圳市海王生物工程股份有限公司（以下简称"公司"）2023 年年度股东 大会（以下简称"本次会议"）于 2024 年 6 月 13 日（星期四）召开。北京德恒 （深圳）律师事务所（以下简称"德恒"）受公司委托，指派曹中海律师、符欣 欣律师（以下简称"德恒律师"）出席了本次会议。根据《中华人民共和国证券 法》（以下简称"《证券法》"）《中华人民共和国公司法》（以下简称"《公 司法》"）中国证券监督管理委员会《上市公司股东大会规则》（以下简称"《股 东大会规则》"）《深圳市海王生物工程股份有限公司章程》（以下简称"《公 司章程》"）的 ...

证券代码：000078 证券简称：海王生物 公告编号：2024-044 深圳市海王生物工程股份有限公司 2023 年年度股东大会决议公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、重要提示 本次会议召开期间无增加、否决或变更提案的情况。 二、会议召开情况 （一）会议召开时间 （1）现场会议：2024 年 6 月 13 日（星期四）下午 14:50 （2）网络投票：2024 年 6 月 13 日（星期四）。其中，通过深圳证券交易所 交易系统进行网络投票时间为 2024 年 6 月 13 日（星期四）上午 9:15-9:25，9:30- 11:30 和下午 13:00-15:00；通过深圳证券交易所互联网投票系统投票时间为 2024 年 6 月 13 日（星期四）9:15-15:00 的任意时间。 （二）现场会议召开地点 深圳市南山区科技园科技中三路 1 号海王银河科技大厦 24 楼会议室 （三）会议召集人 深圳市海王生物工程股份有限公司董事局 （四）投票方式 本次会议采取现场投票与网络投票相结合的方式召开。 本次股东大会通过深圳证券交易所交易系统和互联 ...

特别提示： 深圳市海王生物工程股份有限公司（以下简称"公司"）控股股东深圳海王集 团股份有限公司（以下简称"海王集团"）合计质押公司股份数量为1,214,318,878 股，占其合计持有公司股份数量的比例为99.83%，占公司总股本的44.14%。公司 控股股东质押的股票均为场外质押，质押在银行等金融机构；质押用途基本为融 资增信用途，不存在质押平仓风险。 公司于近日收到公司控股股东海王集团通知获悉：海王集团因业务需要，办 理了其所持公司部分股份的解押及再质押手续。具体情况如下： 证券代码：000078 证券简称：海王生物 公告编号：2024-043 深圳市海王生物工程股份有限公司 关于股东部分股份解押及质押的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 | 股东名称 | 是否为控股 股东或第一 | 本次解除质押股 | 占其所持 | 占公司 | 起始日期 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 一致行动人 | 份数量（股） | 股份比例 | 总 ...

证券代码：000078 证券简称：海王生物 公告编号：2024-042 深圳市海王生物工程股份有限公司 关于筹划重大事项的进展公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，本次重大事项尚未签署正式协议，该事项尚需履行必要 的决策、审批程序。深圳市海王生物工程股份有限公司（以下简称"公司"、"本 公司"或"海王生物"）将继续严格按照有关法律法规及规范性文件的要求，根 据重大事项的进展情况及时履行信息披露义务。本次重大事项尚存在重大不确定 性，敬请广大投资者知悉并注意投资风险。 一、本次交易概况 公司于2022年3月4日披露了《关于筹划重大事项的提示性公告》，公司拟筹 划重大资产重组及控股股东筹划混合所有制改革事项。根据《上市公司重大资产 重组管理办法》《深圳证券交易所上市公司自律监管指引第8号——重大资产重 组》等法规的相关规定，公司每月披露一次本次重大事项的进展情况，具体内容 详见公司于2022年3月4日至本公告披露日在《中国证券报》《证券时报》《证券 日报》《上海证券报》及巨潮资讯网（http://www.cninf ...

证券代码：000078 证券简称：海王生物 公告编号：2024-041 深圳市海王生物工程股份有限公司 关于为控股子公司提供担保实施情况的公告 1、济宁海王华森医药有限公司（以下简称"济宁华森"）向济宁高新村镇 银行股份有限公司申请综合授信额度，苏鲁海王医药集团有限公司为其在该行不 超过人民币1000万元的额度提供连带责任保证担保。 2、陕西海王银河医疗科技有限公司（以下简称"陕西海王"）向重庆银行 股份有限公司西安分行申请综合授信额度，公司与自然人王健共同为其在该行不 超过人民币800万元的额度提供连带责任保证担保。 3、海王医疗配送服务（湖南）有限公司（以下简称"湖南海王医疗配送"） 向长沙农村商业银行股份有限公司远大支行申请综合授信额度，公司、海王医疗 配送服务（广东）有限公司共同为其在该行不超过人民币2000万元的额度提供连 带责任保证担保。 4、海王医疗配送服务（广东）有限公司（以下简称"广东海王医疗配送"） 向上海睿海创世商业保理有限公司申请保理融资服务，公司为其在该公司不超过 人民币1160万元的额度提供连带责任保证担保。 5、江苏海王医疗器械有限公司（以下简称"江苏海王"）向南京银行股份 有限 ...

Financial Performance - The company's operating cash flow net amount for the reporting period was approximately ¥109.48 million, a decrease of ¥41.63 million compared to the previous year[26]. - The company's operating revenue for 2023 was CNY 36,418,770,306.16, a decrease of 3.74% compared to 2022[43]. - The net profit attributable to shareholders was a loss of CNY 1,689,944,687.46, representing a decline of 64.56% year-over-year[43]. - The net cash flow from operating activities was a negative CNY 410,189,287.80, a significant decrease of 537.65% compared to the previous year[43]. - The total assets at the end of 2023 were CNY 32,304,686,545.78, down 10.89% from the previous year[44]. - The net assets attributable to shareholders decreased by 36.00% to CNY 3,002,922,640.59[44]. - The company reported a significant decline in basic and diluted earnings per share, both at -CNY 0.6423, a drop of 64.48% from the previous year[43]. - The company reported a goodwill impairment of CNY 882.25 million, reflecting a significant decrease from the previous period[139]. - The company reported a total revenue of 4,500 million for the year 2023, with a significant increase of 30% compared to the previous year[113]. - The company reported a total of 2,000 million in guarantees for related parties, with a compliance status of "not fulfilled" for some[116]. Market and Industry Trends - In 2023, the domestic GDP reached ¥12,605.82 billion, reflecting a growth of 5.2% year-on-year[28]. - The national pharmaceutical circulation market sales totaled ¥2,751.6 billion in 2022, with a year-on-year growth of 6%[29]. - The pharmaceutical wholesale market sales amounted to ¥2,152.6 billion, with a year-on-year increase of 5.4%[29]. - The pharmaceutical distribution industry is under pressure, with a reported revenue growth of only 6.7% in 2023, down 2.6% from the previous year[31]. - The overall pharmaceutical industry in China saw a decline in key economic indicators, with the industrial added value dropping by 5.2% year-on-year, total revenue decreasing by 4%, and profits falling by 16.2%[60]. Corporate Governance and Shareholder Information - The company has not experienced any changes in its controlling shareholder since its listing on December 18, 1998[20]. - The company plans not to distribute cash dividends or issue bonus shares for the year[11]. - The total number of restricted shares at the beginning of the period was 131,258,412, with 6,498,793 shares released during the period, resulting in 124,759,619 restricted shares at the end of the period[84]. Strategic Initiatives and Future Outlook - The company is focusing on "steady growth, cost control, highlighting new business, and strong execution" as its main management principles for 2023[63]. - The company plans to continue focusing on market expansion and new product development strategies in the upcoming fiscal year[139]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by 2025[113]. - The company has invested 300 million in R&D for new technologies to improve production efficiency[113]. - The company has provided a future outlook with a revenue guidance of 5,000 million for 2024, indicating a projected growth of approximately 11%[113]. Debt and Financial Management - Debt obligations are set to mature in two years, with a total of 657,133.14 million approved for subsidiary guarantees[116]. - The actual guarantee amount for subsidiaries during the reporting period was 525,338.98 million[116]. - The company has a structured approach to managing its debt obligations, ensuring timely repayments[156]. - The company has engaged in multiple debt guarantees, indicating a strategy to secure financing for operations[157]. - The company has a history of issuing debt guarantees, which may impact its future financing strategies[157]. Research and Development - The company is investing 5,200 million in research and development for new technologies aimed at enhancing product offerings and improving operational efficiency[198]. - Research and development expenses for 2023 were ¥47,938,144.82, slightly down from ¥48,433,791.57 in 2022[148]. - New product development includes the launch of three innovative pharmaceutical products, expected to contribute an additional 700 million in revenue[113]. Awards and Recognition - The company has been recognized with multiple awards, including "2022-2023 Annual Pharmaceutical Commercial Top 100 Enterprises" and "2023 China Medical Device Commercial Key Enterprises TOP50"[65]. Internal Control and Compliance - The company is subject to a year-long national campaign to address corruption in the pharmaceutical sector, initiated by ten ministries including the National Health Commission[28]. - The company has implemented changes in accounting policies effective from January 1, 2023, due to new regulations issued by the Ministry of Finance[22]. - The audit opinion was a standard unqualified opinion, indicating no major issues found in the financial statements[125].

Financial Performance - The company's revenue for Q1 2024 was ¥8,087,937,989.71, a decrease of 18.78% compared to ¥9,957,850,383.56 in the same period last year[5] - Net profit attributable to shareholders was ¥42,641,426.53, down 42.79% from ¥74,530,706.41 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0162, a decline of 40.22% compared to ¥0.0271 in the same period last year[5] - Net profit for Q1 2024 was CNY 69,171,556.13, a decline of 37.2% from CNY 110,250,475.24 in Q1 2023[19] - Earnings per share for Q1 2024 were CNY 0.0162, compared to CNY 0.0271 in Q1 2023, reflecting a decrease of 40.3%[19] Cash Flow - The net cash flow from operating activities decreased by 48.16% to ¥56,755,485.31 from ¥109,477,986.68 in the previous year[5] - The company’s cash flow from operating activities showed a decline, indicating potential challenges in maintaining liquidity[20] - The net cash flow from operating activities for Q1 2024 was ¥56,755,485.31, a decrease of 48% compared to ¥109,477,986.68 in Q1 2023[21] - The net cash flow from financing activities was -¥57,851,412.93, contrasting with a positive net cash flow of ¥121,377,969.99 in Q1 2023[22] - The company reported a net cash increase of -¥34,279,836.16 for Q1 2024, compared to an increase of ¥178,380,466.94 in Q1 2023[22] Assets and Liabilities - Total assets increased by 1.11% to ¥32,662,246,219.97 from ¥32,304,686,545.78 at the end of the previous year[5] - The total liabilities as of Q1 2024 amounted to CNY 28,406,589,344.62, an increase from CNY 28,087,241,284.03 in the previous year[16] - The total equity attributable to shareholders of the parent company was CNY 3,045,564,067.12, up from CNY 3,002,922,640.59 in Q1 2023[16] Operating Costs and Expenses - Total operating costs for Q1 2024 were CNY 7,981,269,889.39, down 18.7% from CNY 9,825,719,310.45 in the same period last year[17] - Research and development expenses for Q1 2024 were CNY 10,122,756.35, slightly down from CNY 11,339,139.83 in Q1 2023[17] - The company reported a decrease in sales expenses to CNY 282,240,166.46 from CNY 419,809,578.57 in the same quarter last year, a reduction of 32.8%[17] Investments and Receivables - Long-term receivables increased by 52.77% due to changes in the collection cycle of subsidiary payments[10] - Prepayments rose by 75.51%, primarily due to an increase in equipment leasing payments received by subsidiaries[10] - The company experienced a 130.40% decrease in investment income, attributed to reduced disposal gains from subsidiaries[10] - Long-term equity investments remained stable at RMB 188,513,324.04, showing minimal change from RMB 188,461,054.75[15] - Accounts receivable stood at RMB 17,364,050,205.10, slightly up from RMB 17,356,877,098.26, indicating a marginal increase[15] Cash and Equivalents - The company's cash and cash equivalents increased to RMB 3,769,210,852.99 from RMB 3,480,400,987.64, reflecting a growth of approximately 8.3%[15] - The total cash and cash equivalents at the end of Q1 2024 stood at ¥1,102,450,212.12, slightly down from ¥1,140,882,786.80 at the end of Q1 2023[22] - Cash received from sales and services in Q1 2024 was CNY 8,348,547,159.91, down from CNY 8,938,394,583.73 in Q1 2023[20] Strategic Initiatives - The company plans to transfer 275,083,326 shares, equivalent to 10% of its total share capital, to Guangdong Silk and Textile Group Co., Ltd.[12] - The management is actively engaging with stakeholders to discuss the progress of the planned share transfer and other strategic initiatives[13] - The company is committed to adhering to legal and regulatory requirements regarding the disclosure of significant matters[13]

1、审议通过了《关于全资子公司物流仓库搬迁及拟投资建设新智慧物流园 的议案》 具体内容详见公司于本公告日在《证券时报》《证券日报》《中国证券报》 《上海证券报》及巨潮资讯网上刊登的相关公告。 证券代码：000078 证券简称：海王生物 公告编号：2024-026 深圳市海王生物工程股份有限公司 第九届董事局第十四次会议决议公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、董事局会议召开情况 深圳市海王生物工程股份有限公司（以下简称"公司"或"本公司"）第九届董 事局第十四次会议通知于2024年4月20日发出，并于2024年4月23日以现场及通讯 会议相结合的形式召开。其中独立董事张华先生、张巍松先生，董事张锋先生、 张翼飞先生以出席现场会议的形式参与表决；独立董事王焕军先生，董事张思民 先生、车汉澍先生、沈大凯先生、金锐先生以视频会议形式参与表决。公司监事 胡凯辉先生，公司高级管理人员张晓鹏先生、王云雷先生列席了本次会议。会议 应参与表决董事9人，实际参与表决董事9人。会议的召开和表决程序符合《公司 法》和《公司章程》的规定。 二、董事局会议审议情况 ...